Cibc World Market Inc. Purchases Shares of 58,453 IQVIA Holdings Inc. $IQV

Cibc World Market Inc. acquired a new position in shares of IQVIA Holdings Inc. (NYSE:IQV) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 58,453 shares of the medical research company’s stock, valued at approximately $11,294,000.

A number of other hedge funds have also recently modified their holdings of IQV. Brighton Jones LLC lifted its position in IQVIA by 244.4% in the fourth quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company’s stock valued at $703,000 after acquiring an additional 2,537 shares during the last quarter. Empowered Funds LLC increased its position in shares of IQVIA by 102.1% during the first quarter. Empowered Funds LLC now owns 9,728 shares of the medical research company’s stock worth $1,715,000 after purchasing an additional 4,915 shares in the last quarter. Sivia Capital Partners LLC purchased a new stake in shares of IQVIA in the 2nd quarter valued at about $514,000. First Trust Advisors LP lifted its holdings in shares of IQVIA by 14.8% in the 2nd quarter. First Trust Advisors LP now owns 92,015 shares of the medical research company’s stock valued at $14,501,000 after purchasing an additional 11,845 shares during the last quarter. Finally, NewEdge Advisors LLC boosted its position in shares of IQVIA by 5.4% in the 2nd quarter. NewEdge Advisors LLC now owns 22,731 shares of the medical research company’s stock valued at $3,582,000 after purchasing an additional 1,155 shares during the period. 89.62% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at IQVIA

In related news, insider Bhavik Patel sold 1,855 shares of the business’s stock in a transaction dated Friday, July 31st. The shares were sold at an average price of $235.27, for a total transaction of $436,425.85. Following the sale, the insider owned 1,348 shares of the company’s stock, valued at approximately $317,143.96. The trade was a 57.91% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider W Richard Staub sold 5,500 shares of the business’s stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $232.68, for a total value of $1,279,740.00. Following the sale, the insider owned 13,312 shares in the company, valued at approximately $3,097,436.16. The trade was a 29.24% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 12,913 shares of company stock worth $3,098,793 over the last three months. 1.70% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

IQV has been the topic of several research analyst reports. William Blair raised IQVIA to a “strong-buy” rating in a research report on Tuesday, July 28th. Deutsche Bank Aktiengesellschaft set a $240.00 target price on shares of IQVIA in a research report on Thursday, July 9th. BMO Capital Markets upped their price target on shares of IQVIA from $210.00 to $270.00 and gave the company an “outperform” rating in a research report on Wednesday, July 29th. Royal Bank Of Canada increased their price target on shares of IQVIA from $221.00 to $247.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 29th. Finally, Wall Street Zen raised shares of IQVIA from a “hold” rating to a “buy” rating in a research report on Saturday, August 1st. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $241.88.

IQVIA Price Performance

Shares of IQV opened at $260.30 on Tuesday. The company has a current ratio of 0.71, a quick ratio of 0.71 and a debt-to-equity ratio of 2.18. The stock’s 50 day moving average is $214.97 and its two-hundred day moving average is $187.62. IQVIA Holdings Inc. has a twelve month low of $154.50 and a twelve month high of $261.88. The firm has a market capitalization of $42.85 billion, a PE ratio of 32.30, a P/E/G ratio of 2.21 and a beta of 1.18.

IQVIA (NYSE:IQV) last issued its earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.03 by $0.12. The business had revenue of $4.37 billion during the quarter, compared to the consensus estimate of $4.30 billion. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.The company’s revenue for the quarter was up 8.7% on a year-over-year basis. During the same period in the prior year, the business posted $2.81 EPS. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Research analysts anticipate that IQVIA Holdings Inc. will post 11.57 earnings per share for the current year.

IQVIA declared that its Board of Directors has authorized a stock buyback plan on Thursday, May 7th that allows the company to repurchase $2.00 billion in shares. This repurchase authorization allows the medical research company to repurchase up to 6.8% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company’s board believes its stock is undervalued.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real?world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real?world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.